The NanoCarb is a new Marie Skłodowska-Curie Action about Glyco-Nanoparticles for Applications in Advanced Nanomedicine.
The overarching aim of the NanoCarb ETN project is to develop glycosylated nanoparticles with enhanced therapeutic actions for healthcare applications. 15 Early Stage Researchers (ESRs) recruited for the NanoCarb project will work on their individual ESR projects designed to provide appropriate research goals for PhD students. Each ESR will be exposed to a well-balanced and optimal experience in academia, industry and research centre in order to increase their research experience and scientific maturity.
NanoCarb is coordinated by Marco Monopoli, a StAR Research Lecturer at RCSI and has 9 years of multidisciplinary experience in the bio-nano interactions field to assess nanomaterial behavior in complex media for nanomedicine applications and to understanding the safety and environmental impact.
NanoCarb is recruiting!
The individual ESR projects are designed to provide appropriate research goals for PhD students, which will result in the completion of a research thesis, publications and in the dissemination of the scientific results at international conferences.
Each of the 15 ESRs will be exposed to a well-balanced and optimal experience in academia, industry and research centre in order to increase their research experience and scientific maturity. They will also gain broader experience from spending time in Partner research labs, experiencing different research environments and cultures, and producing well-rounded ‘European’ scientists. Their training will be undertaken in some of the world`s key laboratories for polymer research and in innovative European companies.
All open positions will be published on EURAXESS
ESR1: Fully degradable glycopolypeptide nanoparticles for the delivery of active compounds
Host institution:
Royal College of Surgeons in Ireland, Dublin, Ireland
Planned Secondments:
University of Warwick, Coventry, United Kingdom (2 months)
Ludger Ltd., Oxfordshire, United Kingdom (2 months)
ESR2: Glycopolypeptide grafted silica nanoparticles and their biological interaction
Host institution:
Royal College of Surgeons in Ireland, Dublin, Ireland
Planned Secondments:
MJR PharmJet GmbH, Überherrn, Germany (2 months)
University of Warwick, Coventry, United Kingdom (2 months)
ESR3: Glyco-nanoparticle libraries based on gold/polymer hybrids
Host institution:
University of Warwick, Coventry, United Kingdom
Planned Secondments:
Ludger Ltd., Oxfordshire, United Kingdom (3 months)
Royal College of Surgeons in Ireland, Dublin, Ireland (3 months)
ESR4: Synthesis of smart glycosides to enhance the glyco-nanomaterial circulation half-life
Host institution:
Università degli Studi di Milano, Milan, Italy
Planned Secondments:
Midatech Ltd., Abingdon, United Kingdom (2 months)
Royal College of Surgeons in Ireland, Dublin, Ireland (3 months)
ESR5: Glycan-coated nanoparticles for the enhanced delivery of bioactive compounds
Host institution:
Midatech Ltd., Abingdon, United Kingdom
Planned Secondments:
Royal College of Surgeons in Ireland, Dublin, Ireland (3 months)
Vlaamse Instelling voor Technologisch Onderzoek N.V., Mol, Belgium (2 months)
ESR6: Development of purification and modification strategies of N-type glycopeptide and glycan moieties for use as nanoparticle activity enhancers
Host institution:
Ludger Ltd., Oxfordshire, United Kingdom
Planned Secondments:
University of Warwick, Coventry, United Kingdom (3 months)
Royal College of Surgeons in Ireland, Dublin, Ireland (4 months)
ESR7: Development of synthetic and natural nano-glycomaterials with defined corona for enhanced blood circulation and low immunogenicity
Host institution:
Royal College of Surgeons in Ireland, Dublin, Ireland
Planned Secondments:
Ludger Ltd., Oxfordshire, United Kingdom (4 months)
CIC biomaGUNE, San Sebastian, Spain (4 months)
ESR8: Biological analysis of lecting binding capacity
Host institution:
University of Warwick, Coventry, United Kingdom
Planned Secondments:
Midatech Ltd., Abingdon, United Kingdom (3 months)
CIC biomaGUNE, San Sebastian, Spain (3 months)
ESR9: In vitro studies of the stability of protein corona around glyco NPs and biological fate
Host institution:
CIC biomaGUNE, San Sebastian, Spain
Planned Secondments:
Midatech Ltd., Abingdon, United Kingdom (3 months)
Royal College of Surgeons in Ireland, Dublin, Ireland (3 months)
ESR10: In vitro biocompatibility assay for glyconano-conjugates
Host institution:
Royal College of Surgeons in Ireland, Dublin, Ireland
Planned Secondments:
Attana AB, Stockholm, Sweden (6 months)
University of Warwick, Coventry, United Kingdom (3 months)
ESR11: Biosensing platform for lectin detection related to cerebrovascular disease using nanoplasmonics
Host institution:
Vlaamse Instelling voor Technologisch Onderzoek N.V., Mol, Belgium
Planned Secondments:
University of Warwick, Coventry, United Kingdom (2 months)
Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy (4 months)
ESR12: Evaluation and optimisation of glycan-coated gold nanoparticles for selective accumulation
to tumour tissue
Host institution:
Midatech Ltd., Abingdon, United Kingdom
Planned Secondments:
Royal College of Surgeons in Ireland, Dublin, Ireland (4 months)
Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy (4 months)
ESR13: Glycan-coated nanoparticles as inhibitors of specific lectins, a new neuroprotective therapeutic strategy for brain injury caused by ischemia
Host institution:
Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Planned Secondments:
Università degli Studi di Milano, Milan, Italy (2 months)
Attana AB, Stockholm, Sweden (3 months)
ESR14: In vivo fate studies of glyco NPs and biocorona stability
Host institution:
CIC biomaGUNE, San Sebastian, Spain
Planned Secondments:
Università degli Studi di Milano, Milan, Italy (2 months)
Vlaamse Instelling voor Technologisch Onderzoek N.V., Mol, Belgium (3 months)
ESR15: Evaluation of the role of surface functionalization of Glyco-NP on the distribution, excretion and crossing of biological barriers in healthy and pathologic mice
Host institution:
Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Planned Secondments:
Royal College of Surgeons in Ireland, Dublin, Ireland (3 months)
Vlaamse Instelling voor Technologisch Onderzoek N.V., Mol, Belgium (3 months)